var data={"title":"Polyethylene glycol 3350: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Polyethylene glycol 3350: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/160261?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=polyethylene-glycol-3350-patient-drug-information\" class=\"drug drug_patient\">see &quot;Polyethylene glycol 3350: Patient drug information \t&quot;</a> and <a href=\"topic.htm?path=polyethylene-glycol-3350-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Polyethylene glycol 3350: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2295346\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>GaviLAX [OTC];</li>\n      <li>GlycoLax [OTC];</li>\n      <li>HealthyLax [OTC];</li>\n      <li>MiraLax [OTC];</li>\n      <li>PEGyLAX</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23536048\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Relaxa;</li>\n      <li>Restoralax</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2295350\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Laxative, Osmotic</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2295373\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bowel preparation before colonoscopy (off-label use):</b> Oral: 17 g (~1 heaping tablespoon) in 240 mL (8 ounces) of clear liquid every 10 minutes until 2,000 mL of volume are consumed (start within 6 hours after administering bisacodyl delayed-release tablets or magnesium citrate) (ASCRS/ASGE/SAGES [Wexner 2006])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Constipation, occasional:</b> Oral: 17 g (~1 heaping tablespoon) dissolved in 120 to 240 mL (4 to 8 ounces) of beverage, once daily; do not use for &gt;1 to 2 weeks (product specific) unless directed by health care provider. In a clinical trial, 34 g once daily was shown to be effective, but with increased adverse effects (DiPalma 1999).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7814689\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=polyethylene-glycol-3350-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Polyethylene glycol 3350: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Bowel preparation before colonoscopy (off-label):</b> Children &gt;2 years of age and Adolescents: Limited data available: Oral: 1.5 g/kg/day for 4 days; maximum dose: 100 g/<b>day</b> (Pashankar 2004)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Constipation, occasional (off-label use):</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infants, Children, and Adolescents &lt;17 years of age: Oral: 0.2 to 0.8 g/kg/day (NASPGHAN [Tabbers 2014]); higher initial dose of 1 g/kg has been suggested (Loening-Baucke 2004; Pashankar 2001); maximum daily dose: 17 g/day. <b>Note:</b> Dosage should be individualized to achieved desired effect, infants and young children may require higher doses than school-aged children (Loening-Buck 2004; Pashankar 2001)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adolescents &ge;17 years of age: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Fecal impaction, slow disimpaction (off-label use):</b> Limited data available: Children and Adolescents: Oral: 1 to 1.5 g/kg daily for 3 to 6 consecutive days (NASPGHAN [Tabbers] 2014; Youssef 2002); maximum daily dose: 100 g/<b>day</b> (Youssef 2002); following disimpaction maintenance dose of 0.4 g/kg daily should be continued for &ge;2 months (NASPGHAN [Tabbers] 2014)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2482702\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45114965\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45114966\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2295374\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Packet, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">HealthyLax:  (1 ea, 14 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MiraLax:  (1 ea, 10 ea, 12 ea, 24 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic:  (1 ea, 14 ea, 30 ea, 100 ea)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Powder, Oral: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GaviLAX: 17 g/dose (238 g, 510 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">GlycoLax: 17 g/dose (119 g, 255 g, 527 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MiraLax: 17 g/dose (1 ea, 119 g, 238 g, 510 g, 765 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">PEGyLAX: 17 g/dose (527 g)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 17 g/dose (119 g, 238 g, 250 g [DSC], 255 g, 500 g [DSC], 510 g, 527 g, 850 g)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2295348\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F23536067\" class=\"block foccan drugH1Div\"><span class=\"drugH1\">Dosage Forms: Canada</span>\n    <p style=\"text-indent:0em;display:inline\">Information with regard to form, strength, and availability of products uniquely available in Canada but currently not available in the US. Refer also to Dosage forms.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Powder, Oral: 17 g/dose (238 g, 510 g)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sachet, Oral: 17 g/sachet (4 ea, 14 ea)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F7814690\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Constipation, occasional: Stir powder in 120 to 240 mL (4 to 8 ounces) of water, juice, soda, coffee, or tea until dissolved and administer immediately.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bowel preparation for colonoscopy (off-label use): Administer bisacodyl delayed-release tablets or magnesium citrate prior to polyethylene glycol administration. After bowel movement (or up to 6 hours later if no bowel movement), stir powder in 240 mL (8 ounces) of clear liquid until dissolved and administer immediately. Dose is repeated every 10 minutes until 2,000 mL of volume is consumed.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2295351\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Constipation, occasional:</b> Treatment of occasional constipation</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25744662\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Bowel preparation before colonoscopy; Occasional constipation (infants, children, adolescents &lt;17 years)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2295345\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">MiraLax may be confused with Mirapex</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Polyethylene glycol 3350 may be confused with polyethylene glycol electrolyte solution</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">International issues:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">MiraLax may be confused with Murelax brand name for oxazepam [Australia]</p>\n        <p style=\"text-indent:-2em;margin-left:4em;\">Polyethylene glycol 3350 may be confused with polyethylene glycol 4000 [international markets]</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2295361\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Frequency not defined.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dermatologic: Urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Gastrointestinal: Abdominal cramps, bloating of the stomach, diarrhea, flatulence, nausea</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2295357\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Hypersensitivity to polyethylene glycol or any component of the formulation; known or suspected bowel obstruction</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">OTC labeling: When used for self-medication, do not use if you have renal disease unless advised by a health care provider</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Canadian labeling:</i> Additional contraindications (not in US labeling): Relaxa: Use in children &lt;18 years of age unless advised by a physician</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2295358\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electrolyte imbalance: Prolonged, frequent, or excessive use may lead to electrolyte imbalance.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity:  Do not use if you are hypersensitive to polyethylene glycol. If an allergic reaction develops (eg, rash, swelling, difficulty breathing), discontinue use immediately and seek medical care.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concern:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bowel obstruction: Evaluate patients with symptoms of bowel obstruction, appendicitis, or inflamed bowel (nausea, vomiting, abdominal pain or distension) prior to use; use is contraindicated in patients with known or suspected bowel obstruction.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: Use with caution in patients with renal impairment. Do not use in renal impairment unless under supervision of a health care professional.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Administration: If severe diarrhea occurs, discontinue use. When used for bowel preparation for colonoscopy (off-label use), oral medications should not be administered within 1 hour of start of therapy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Duration of therapy: Do not use for longer than 1 to 2 weeks (product specific); 2 to 4 days may be required to produce bowel movement.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; OTC labeling: When used for self-medication, patients should consult health care provider prior to use if they have nausea, vomiting, or abdominal pain, irritable bowel syndrome, or a sudden change in bowel habits for &gt;2 weeks. Patients should be instructed to discontinue use and consult health care provider if they have severe diarrhea, rectal bleeding, if abdominal pain, bloating, cramping, or nausea gets worse, or if need to use for &gt;1 week.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299899\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6222409\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=10231&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Digoxin: Polyethylene Glycol 3350 may decrease the serum concentration of Digoxin. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2295354\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Polyethylene glycol (PEG) has minimal systemic absorption and would be unlikely to cause fetal malformations. However, until additional information is available, use to treat constipation in pregnancy should be avoided unless other preferred methods are inadequate (Mahadevan 2006). Use as a bowel preparation prior to colonoscopy in pregnant women may be considered (Wexner 2006).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2295368\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">An osmotic agent, polyethylene glycol 3350 causes water retention in the stool; increases stool frequency.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F2295370\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Onset of action: Oral: 24 to 96 hours</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Absorption: Minimal (&lt;0.28%; Pelham, 2008)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Feces (93%); urine (0.2%) (Pelham, 2008)</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Bell EA and Wall GC, &ldquo;Pediatric Constipation Therapy Using Guidelines and Polyethylene Glycol 3350,&rdquo; <i>Ann Pharmacother</i>, 2004, 38(4):686-93.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/14990783/pubmed\" target=\"_blank\" id=\"14990783\">14990783</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Candy D and Belsey J, &ldquo;Macrogol (Polyethylene Glycol) Laxatives in Children With Functional Constipation and Faecal Impaction: A Systematic Review,&rdquo; <i>Arch Dis Child</i>, 2009, 94(2):156-60.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/19019885/pubmed\" target=\"_blank\" id=\"19019885\">19019885</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Co-Minh HB, Demoly P, Guillot B, et al, &ldquo;Anaphylactic shock After Oral Intake and Contact Urticaria Due to Polyethylene Glycols,&rdquo; <i>Allergy</i>, 2007, 62(1):92-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/17156356/pubmed\" target=\"_blank\" id=\"17156356\">17156356</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    DiPalma JA. Braintree polyethylene glycol (PEG) laxative for ambulatory and long-term care facility constipation patients: report of randomized, cross-over trials. 1999. http://web.archive.org/web/20011216021050/http:/www.ojdh.org:80/current.dir/dipalma_braintree.html#top. Accessed August 31, 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    GaviLAX (polyethylene glycol 3350) [prescribing information]. Somerset, NJ: Gavis Pharmaceuticals; June 2015.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Loening-Baucke V, &ldquo;Prevalence, Symptoms and Outcome of Constipation in Infants and Toddlers,&rdquo; <i>J Pediatr</i>, 2005,146(3):359-63.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/15756220/pubmed\" target=\"_blank\" id=\"15756220\">15756220</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Loening-Baucke V, Krishna R, and Pashankar DS, &ldquo;Polyethylene Glycol 3350 Without Electrolytes for the Treatment of Functional Constipation in Infants and Toddlers,&rdquo; <i>J Pediatr Gastroenterol Nutr</i>, 2004, 39(5):536-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/15572895/pubmed\" target=\"_blank\" id=\"15572895\">15572895</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mahadevan U and Kane S, &quot;American Gastroenterological Association Institute Technical Review on the Use of Gastrointestinal Medications in Pregnancy,&quot; <i>Gastroenterology</i>, 2006, 131(1):283-311.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/16831611/pubmed\" target=\"_blank\" id=\"16831611\">16831611</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Michail S, Gendy E, Preud&rsquo;Homme D, et al, &ldquo;Polyethylene Glycol for Constipation in Children Younger Than Eighteen Months Old,&rdquo; <i>J Pediatr Gastroenterol Nutr</i>, 2004, 39(2):197-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/15269628/pubmed\" target=\"_blank\" id=\"15269628\">15269628</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MiraLax (polyethylene glycol 3350) [product information]. Whitehouse Station, NJ: Schering-Plough; August 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Nurko S, Youssef NN, Sabri M, et al, &ldquo;PEG3350 in the Treatment of Childhood Constipation: A Multicenter, Double-Blinded, Placebo-Controlled Trial,&rdquo; <i>J Pediatr</i>, 2008 153(2):254-61.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/18534221/pubmed\" target=\"_blank\" id=\"18534221\">18534221</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pashankar DS, Bishop WP. Efficacy and optimal dose of daily polyethylene glycol 3350 for treatment of constipation and encopresis in children. <i>J Pediatr</i>. 2001;139(3):428-432.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/11562624/pubmed\" target=\"_blank\" id=\"11562624\">11562624</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pashankar DS, Bishop WP, and Loening-Baucke V, &ldquo;Long-term Efficacy of Polyethylene Glycol 3350 for the Treatment of Chronic Constipation in Children With and Without Encopresis,&rdquo; <i>Clin Pediatr (Phila)</i>, 2003, 42(9):815-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/14686553/pubmed\" target=\"_blank\" id=\"14686553\">14686553</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pashankar DS, Loening-Baucke V, and Bishop WP, &ldquo;Safety of Polyethylene Glycol 3350 for the Treatment of Chronic Constipation in Children,&rdquo; <i>Arch Pediatr Adolesc Med</i>, 2003, 157(7):661-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/12860787/pubmed\" target=\"_blank\" id=\"12860787\">12860787</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pashankar DS, Uc A, Bishop WP. Polyethylene glycol 3350 without electrolytes: a new safe, effective, and palatable bowel preparation for colonoscopy in children.<i> J Pediatr.</i> 2004;144(3):358-362. doi: 10.1016/j.jpeds.2003.11.033.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/15001943/pubmed\" target=\"_blank\" id=\"15001943\">15001943</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Pelham RW, Nix LC, Chavira RE, et al, &ldquo;Clinical Trial: Single- and Multiple-Dose Pharmacokinetics of Polyethylene Glycol (PEG-3350) in Healthy Young and Elderly Subjects,&rdquo; <i>Aliment Pharmaco Ther</i>, 2008, 28(2):256-65.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/18462266/pubmed\" target=\"_blank\" id=\"18462266\">18462266</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Polyethylene Glycol 3350 [prescribing information]. Princeton, NJ: Kremers Urban Pharmaceuticals; August 2011.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Relaxa (polyethylene glycol 3350) [product information]. Mississauga, Ontario, Canada: Red Leaf Medical; March 2014.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Safder S, Demintieva Y, Rewalt M, et al, &ldquo;Stool Consistency and Stool Frequency are Excellent Clinical Markers for Adequate Colon Preparation After Polyethylene Glycol 3350 Cleansing Protocol: A Prospective Clinical Study in Children,&rdquo; <i>Gastrointest Endosc</i>, 2008, 68(6):1131-35.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/18950761/pubmed\" target=\"_blank\" id=\"18950761\">18950761</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Tabbers MM, DiLorenzo C, Berger MY, et al. Evaluation and treatment of functional constipation in infants and children: evidence-based recommendations from ESPGHAN and NASPGHAN. <i>J Pediatr Gastroenterol Nutr</i>. 2014;58(2):258-274.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/24345831/pubmed\" target=\"_blank\" id=\"24345831\">24345831</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    van den Berg MM, van Rossum CH, de Lorijn F, et al, &ldquo;Functional Constipation in Infants: A Follow-Up Study,&rdquo; <i>J Pediatr</i>, 2005, 147(5):700-4.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/16291368/pubmed\" target=\"_blank\" id=\"16291368\">16291368</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Voskuijl W, de Lorijn F, Verwijs W, &ldquo;PEG 3350 (Transipeg) Versus Lactulose in the Treatment of Childhood Functional Constipation: A Double-blind, Randomised, Controlled, Multicentre Trial,&rdquo; <i>Gut</i>, 2004, 53(11):1590-94.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/15479678/pubmed\" target=\"_blank\" id=\"15479678\">15479678</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"16741637\"></a>Wexner SD, Beck DE, Baron TH, et al, &ldquo;A Consensus Document on Bowel Preparation Before Colonoscopy: Prepared by a Task Force from The American Society of Colon and Rectal Surgeons (ASCRS), The American Society for Gastrointestinal and Endoscopy (ASGE) and The Society of American Gastrointestinal and Endoscopic Surgeons (SAGES),&rdquo; <i>Dis Colon Rectum</i>, 2006, 49(6):792-809.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/16741637/pubmed\" target=\"_blank\" id=\"16741637\">16741637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Youssef NN, Peters JM, Henderson W, et al. Dose response of PEG 3350 for the treatment of childhood fecal impaction.<i> J Pediatr.</i> 2002;141(3):410-414. doi: 10.1067/mpd.2002.126603.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/polyethylene-glycol-3350-drug-information/abstract-text/12219064/pubmed\" target=\"_blank\" id=\"12219064\">12219064</a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 10231 Version 137.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F2295346\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F23536048\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F2295350\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F2295373\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F7814689\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F2482702\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F45114965\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F45114966\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F2295374\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F2295348\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms: Canada\" href=\"#F23536067\" class=\"outlineLink\">Dosage Forms: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F7814690\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F2295351\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25744662\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F2295345\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F2295361\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F2295357\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F2295358\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299899\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6222409\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F2295354\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F2295368\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F2295370\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/10231|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=polyethylene-glycol-3350-patient-drug-information\" class=\"drug drug_patient\">Polyethylene glycol 3350: Patient drug information \t</a></li><li><a href=\"topic.htm?path=polyethylene-glycol-3350-pediatric-drug-information\" class=\"drug drug_pediatric\">Polyethylene glycol 3350: Pediatric drug information</a></li></ul></div></div>","javascript":null}